Building Post-IPO Excellence at Centessa Pharmaceuticals
-
2025年10月02日
-
After raising more than $370 million during its IPO in May 2021, Centessa Pharmaceuticals (“Centessa”), a clinical-stage pharmaceutical company, engaged FTI Consulting to support financial reporting and Sarbanes-Oxley Act (“SOX”) compliance during a critical growth period.
Our Impact:
- Centessa received critical and timely support throughout its quarterly financial close periods, reporting and coordination with its auditing partner.
- Centessa’s SOX material weaknesses post-IPO were remediated through control documentation and policy development.
- The finance tech roadmap and accounting staff training developed by FTI Consulting enabled scalable operations for Centessa’s continued growth.
Our Role:
- FTI Consulting analyzed vendor contracts, created standardized accrual packages and ensured accurate quarterly close processes.
- Our experts led data validation during the enterprise resource planning (“ERP”) transition and built supporting tools for ongoing use.
- We developed SOX-scoping documentation, risk assessments and key account policies and provided interim controllership support and finance transformation advisory.
相关服务
相关信息
发布于
2025年10月02日
主要联络人
资深董事总经理
Senior Managing Director, Global Leader of OCFO Solutions
Director